Amadeus Capital Partners

iPremom offers MaiRa, a clinician-prescribed prenatal blood test that estimates a pregnant woman’s risk of preeclampsia from week 9. It analyzes cell-free RNA in maternal blood with a proprietary predictive algorithm, giving obstetric teams an early risk report to guide monitoring and preventive decisions; it is a risk-assessment tool, not a diagnostic test.

AI-powered platform to detect and respond to disinformation and hybrid threats